莫克西布斯提缓解了性结肠炎大鼠的肠道炎症,通过调节长非编码RNALOC108352929并抑制Phf11表达
Guona Li1,2, Chen Zhao2,3, Jing Xu1
1Yueyang Hospital of Integrative Chinese and Western Medicine, Shanghai University of Traditional Chinese Medicine, Shanghai, 200437, China.
Heliyon
|March 5, 2024
概括
摩克西布斯有效地治疗性结肠炎 (UC),通过减少肠道炎症和调节长非编码RNA (lncRNA) 表达. 这种传统疗法通过向LOC108352929-Phf11途径,对UC管理具有前途.
科学领域:
- 胃肠病学 胃肠病学
- 分子生物学分子生物学
- 传统中国医药 传统中国医药
背景情况:
- 性结肠炎 (UC) 的发病包括长非编码RNAs (lncRNAs).
- 传统中医药中的moxibustion显示出对UC的治疗潜力.
- 在UC中莫克西布斯的特定分子机制,特别是涉及lncRNAs,仍然不清楚.
研究的目的:
- 研究moxibustion对肠粘膜炎的作用,在UC的老鼠模型中.
- 探索lncRNAs和mRNA表达特征在moxibustion治疗作用中的作用.
- 确定UC中moxibustion治疗的潜在分子标记物.
主要方法:
- 通过使用硫酸 (DSS) 建立了一个UC大鼠模型.
- 鼠被用催化剂 (MOX) 或硫素 (SASP) 治疗.
- 评估了疾病活动指数 (DAI),组织病理学得分和炎症性细胞因子水平 (TNF-α,IFN-γ,IL-1β). 分析了结肠的lncRNA和mRNA表达特征,并检查了特定的基因表达 (LOC108352929,Phf11,NF-κB) 在体内和体外.
主要成果:
- 在UC大鼠中,moxibustion显著降低了DAI,他的病理学得分和结肠炎症标志物 (TNF-α,IFN-γ,IL-1β).
- 催化剂改变了lncRNA和mRNA的表达,上调了LOC108352929和下调了Phf11.
- 催化剂降低了Phf11和NF-κB的局部化,而LOC108352929的敲除在体外增加了TNF-αmRNA的表达.
结论:
- 在UC大鼠中,moxibustion有效地改善了DSS诱导的结肠损伤和炎症.
- 催化剂调节lncRNA-mRNA联合表达网络,特别影响LOC108352929和Phf11.
- LOC108352929-Phf11轴可以作为UC.moxibustion治疗的潜在生物标志物.
相关概念视频
01:29Drugs for Treatment of Ulcerative Colitis in IBD
141
Ulcerative colitis is a chronic inflammatory condition primarily affecting the colon and rectum. The primary drugs used in the treatment of ulcerative colitis are aminosalicylates. They exhibit anti-inflammatory and immunosuppressive properties. They modulate inflammatory mediators and inhibit the activity of nuclear factor κB (NF-κB). Aminosalicylates also reduce inflammation by inhibiting prostaglandin and leukotriene production and decreasing neutrophil chemotaxis and superoxide...
141
01:27Inflammatory Bowel Disease I: Ulcerative Colitis
184
Introduction
Inflammatory bowel disease, or IBD, encompasses a group of disorders characterized by chronic inflammation or ulceration of the gastrointestinal tract.
Risk Factors
The exact cause of IBD remains unclear, although it is believed to be due to a mix of genetic, environmental, microbial, and immune factors. Genetic factors are significant in determining susceptibility to IBD, with family history being a critical risk factor. Individuals with a first-degree relative who has IBD are at...
Inflammatory bowel disease, or IBD, encompasses a group of disorders characterized by chronic inflammation or ulceration of the gastrointestinal tract.
Risk Factors
The exact cause of IBD remains unclear, although it is believed to be due to a mix of genetic, environmental, microbial, and immune factors. Genetic factors are significant in determining susceptibility to IBD, with family history being a critical risk factor. Individuals with a first-degree relative who has IBD are at...
184
01:20Drugs for Peptic Ulcer Disease: Prostaglandin Analogs as Mucosal Protective Agents
435
The gastric mucosa produces prostaglandins E2 (PGE2) and prostacyclin (PGI2), crucial in maintaining gastric health. They exert cytoprotective effects, including increasing bicarbonate secretion, releasing protective mucin, reducing gastric acid output, and preventing harmful vasoconstriction. These effects are mediated through various receptors, such as EP1, EP2, EP3, and EP4.
Non-steroidal anti-inflammatory drugs (NSAIDs) can induce peptic ulcers by inhibiting cyclooxygenase, decreasing...
Non-steroidal anti-inflammatory drugs (NSAIDs) can induce peptic ulcers by inhibiting cyclooxygenase, decreasing...
435
01:29Inflammatory Bowel Disease IV: Pharmacological Management
127
Upon diagnosis, managing Inflammatory Bowel Disease (IBD) involves addressing several crucial aspects. The primary goals include resting the bowel, correcting malnutrition, and providing symptomatic relief. Resting the bowel may consist of medications to reduce inflammation and promote healing. Correcting malnutrition is essential, often requiring dietary adjustments and nutritional supplements. Symptomatic relief aims to ease pain, diarrhea, and other discomforts in IBD.
Pharmacologic...
Pharmacologic...
127
01:30Peptic Ulcer Disease I: Introduction
168
Peptic Ulcer Disease (PUD) is characterized by mucosal excavation in the esophagus, stomach, pylorus, or duodenum. It can manifest as acute or chronic based on the extent and duration of mucosal involvement.
An acute ulcer, marked by superficial erosion and minimal inflammation, swiftly resolves upon identifying and addressing the underlying cause. In contrast, a chronic ulcer persists, potentially eroding through the muscular wall and forming fibrous tissue.
Peptic ulcers can also be...
An acute ulcer, marked by superficial erosion and minimal inflammation, swiftly resolves upon identifying and addressing the underlying cause. In contrast, a chronic ulcer persists, potentially eroding through the muscular wall and forming fibrous tissue.
Peptic ulcers can also be...
168
01:24Pathophysiology of Peptic Ulcer Disease: Mucosal Defense Factors
429
Peptic ulcer disease, commonly called PUD, represents a multifaceted condition characterized by disruptions in the lining of the gastrointestinal (GI) tract. Central to the protection of the gastrointestinal lining is the mucosal-bicarbonate barrier. This physiological defense mechanism is a formidable shield against the corrosive effects of gastric acid and pepsin secretion in the stomach. Its role is pivotal in maintaining the structural integrity of the stomach's inner lining.
429